Search PubMed⌕ Search

Biomedical subjects

A Forgione

Publications and source records attributed to A Forgione.

At least 37 records · Page 2Linked to original sources
PubMed1988

Pharmacokinetics of benperidol in volunteers after oral administration.

Benperidol in a 4 mg single dose was administered orally to five healthy male volunteers. The drug was rapidly absorbed (tmax = 2.27 +/- 0.57 h) and largely distributed, the volume of distribution being 5.19 +/- 1.99 l.kg-1. Elimination half-life was 7.65 +/- 2.14 h. Urinary excretion represented only a minimal fraction of ingested dose (0.1 +/- 0.007%). Variability of the area under the curve makes a first-pass metabolism a reasonable possibility. Acute dystonias appeared in two subjects.

Administration, Oral↗
PubMed1988

Stereospecific disposition of flunoxaprofen enantiomers in human beings.

The absorption and disposition kinetics of the enantiomers of the nonsteroidal antiinflammatory drug flunoxaprofen were studied in six healthy volunteers after oral administration of either R,S(+/-)-flunoxaprofen or R(-)-flunoxaprofen. The apparent values of the volume of distribution and systemic clearance of the S(+)-enantiomer were significantly lower than those of the R(-)-enantiomer. There was no significant difference in the absorption and elimination half-lives between the two isomers. The S(+)- to R(-)-isomer plasma concentration ratio increased with time with an apparent inversion half-time of about 50 h. This observation suggests metabolic inversion of R(-)- to S(+)-enantiomer, although the possibilities of stereoselective bioavailability or interaction between the two isomers can not be excluded.

Adult↗
PubMed1987

Interference of the new antiinflammatory compound flunoxaprofen with eicosanoid formation in various biological systems.

S-(+)-2-(4-Fluorophenyl)-alpha-methyl-5-benzoxazolacetic acid (flunoxaprofen, Priaxim is a new antiinflammatory compound, which in various biological systems interferes with the generation and release of arachidonic acid metabolites of the cyclo-oxygenase pathways without affecting the formation of 5- and 12-lipoxygenase products. Flunoxaprofen reduces the concentration of thromboxane (TX)B2 (ED50 = 35.4 mg/kg p.o.) and prostaglandin (PG)E2-like activity (ED50 = 39.9 mg/kg p.o.) in the inflammatory exudate of rats 8 h after implantation of sponges soaked with carrageenan, whereas the concentration of leukotriene (LT)B4 remains in the range of that of the untreated animals (3.1 ng/ml). Flunoxaprofen inhibits cell infiltration in the exudate and this suggests that LTB4 does not initiate cell recruitment but may represent a mechanism for amplifying the inflammatory response. Using human platelets challenged with collagen, flunoxaprofen only at higher concentration (10(-4) mol/l) reduces TXB2 formation without altering generation of 12-hydroxy-5,8,10,14-eicosatetraenoic acid. This suggests a low capacity of flunoxaprofen of affecting platelet aggregation regulated by arachidonic acid metabolites. Flunoxaprofen prevents pulmonary changes due to secondary release of TXA2 in the guinea-pig. In fact this drug prevents changes due to immunological reaction and antagonizes bronchoconstriction due to exogenous administration of histamine and LTC4.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1987

Flunoxaprofen pharmacokinetics in elderly subjects.

Plasma kinetics and 24 h urinary elimination of flunoxaprofen, a nonsteroidal antiinflammatory drug, were studied in 23 elderly patients (mean age 69.9 years) and compared with the data obtained in four young volunteers. The drug was administered as a single oral 100 mg tablet and its plasma and urine concentrations were assayed by a high performance liquid chromatography method. Plasma kinetics fitted a 3-exponential equation with a mean half-life of 7.9 +/- 2.17 hours and a mean peak plasma of 8.5 +/- 2.97 micrograms/ml, which was observed at about the second hour. The values of the areas under the curves (AUC) and the values of total clearance (multiplied by the bioavailability) showed great variability, due to the large differences in the patients body weights; in fact the value of AUC was linearly correlated to the dose divided by the body weight. The mean residence time (MRT) of the drug in plasma was equal to 12.81 h. Low amounts of unmodified drug (about 10%) were found in 24 h urine sample, indicating a high degree of biotransformation. Small differences only were found in plasma kinetics of flunoxaprofen among the present group of elderly patients and the group of four young volunteers; the main difference corresponded to a slower rate of gastrointestinal absorption and to a longer mean residence time.

Aged↗
PubMed1985

Multicentre clinical study with flunoxaprofen in osteoarthritis: preliminary data on 154 patients.

Flunoxaprofen S-(+)-2 [p-fluorophenyl]-alpha-methyl-5-benzoxazole acetic acid, a new propionic acid derivative, was studied to investigate its long-term effectiveness and tolerability in the management of osteoarthritis (OA). To the study were admitted 154 patients suffering from radiologically proven OA of the large joints; 37% of them were hospitalized. The patients received flunoxaprofen 100 mg twice daily for a period of 45-60 days. The variables investigated were: pain at rest, pain on passive motion and pain on active motion with or without load, quality of sleep, articular flexion. In addition, the usual clinical and laboratory controls were carried out (arterial blood pressure, hepatic and renal function tests, haematological examinations). The assessments were made before and at 15, 30, 45 and 60 days of treatment. The results obtained show significant improvements for all variables considered and a very good tolerability of the drug concerning either laboratory controls or adverse reactions.

Adult↗
PubMed1985

Absorption and disposition kinetics of flunoxaprofen and benoxaprofen in healthy volunteers.

Flunoxaprofen is a new nonsteroidal antiinflammatory agent that, like benoxaprofen, inhibits leukotriene rather than prostaglandin synthesis. The absorption and disposition kinetics of flunoxaprofen and benoxaprofen have been compared in six healthy volunteers after oral administration of 100 mg of each drug. The two drugs showed similar absorption characteristics, whereas the distribution and elimination processes were much faster for flunoxaprofen. The renal route of elimination appeared to contribute significantly less to the disposition of flunoxaprofen. These kinetic characteristics render less likely the risk of excessive drug accumulation with flunoxaprofen, especially in the presence of reduced renal function.

Adult↗
PubMed1984

Can pharmacologic hyperprolactinemia and breast-suction induce lactation in women with normal menstrual cycles?

Six women--age range 21/24--with regular ovulatory cycles, voluntarily underwent with L-Sulpiride (100 mg/die) from the 5th to the 19th day of the cycle. On the 13th, 14th and 15th day of therapy breast suction by syringe breast-pump was performed on each woman every 6 hours and for 4' from either breast. Milk secretion was poor and showed no noticeable increase in the three days of breast suction. L-Sulpiride-induced hyperprolactinemia combined with nipple stimulation-induced increased PRL secretion failed to stimulate milk secretion at a level comparable with physiologic lactation in puerperium.

Adult↗
PubMedDate not supplied

Effect of fipexide on passive avoidance behaviour in rats.

The effect of fipexide, administered at different intervals after the learning trial of a single step-through type passive avoidance situation was studied. The administration of fipexide immediately after the learning trial resulted in a long-lasting facilitation of passive avoidance behaviour. On the contrary, the administration of this compound 1 h prior to the retention test failed to influence passive avoidance behaviour. The results suggest that fipexide facilitates memory consolidation but does not influence retrieval processes.

Animals↗
PubMedDate not supplied

Potential fear-provoking patient experiences during treatment.

During a four-month period in 1998, 250 new patients arriving at the General Dentistry Clinic of Tufts University School of Dental Medicine were asked to complete a questionnaire regarding behavior by dental professionals and its effect on dental care. Surveys were returned by 121 women and 82 men, who evaluated seven behaviors from five previously determined categories of anxiety. Age and gender were the only factors considered in analyzing the results. The data suggest that dentists often may exhibit a variety of negative behaviors and attitudes. These can cause increased levels of concern in patients and may act as fear-provoking stimuli, leading to increased fear and avoidance of dental treatment.

Adolescent↗
PubMedDate not supplied

Effect of sulpiride on ischemia- and reperfusion-induced heart damage, in rats.

In an experimental model of heart ischemia, obtained in anesthetized rats with the permanent ligature of the left anterior descending coronary artery, the intravenous (iv) injection of I-sulpiride (6-25 micrograms/kg) dose-dependently reduced the lethality rate, the incidence and severity of ventricular dysrhythmias and infarct size during the early phase of ischemia (first 30 min after coronary ligation). Lethality and there incidence and duration of ventricular dysrhythmias were also significantly reduced by the same IV doses of I-sulpiride in a model of coronary reperfusion. These results show that a specific dopamine antagonist is able to limit ischemia- and reperfusion-induced myocardial damage and suggest that endogenous dopamine may exert a deleterious effect in such conditions.

Animals↗